Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

This was the statement attributed to the CEO:
"Given heparin is dosed at such low concentrations, we wouldnt anticipate any large effect of Heparin on Brilacidin's blocking property in the COVID trial."
My comment ("Besides, last I heard the amount of heparin used wouldn't have had a significant effect") was consistent with that statement and I'm not sure what you mean by his statement not being definitive.



"As to the paper, I did not see a mention of Brilacidin at that link."
I didn't say or suggest that it was mentioned.

I'm a good half a dozen steps out of my comfort zone, but:
I linked the 2014 paper because (1)two of its authors, Scott and Degrado, are names I'm sure you recognize who were involved with B in the pmx-30063 days, (2)the paper is entitled "De novo design of self-assembling foldamers that inhibit heparin-protein interactions" and (3)brilacidin is "a short arylamide foldamer".

I'll gladly admit that I don't know if there's a meaningful connection there or if a self-assembling foldamer and a short arylamide foldamer have anything to do with each other, but I have the feeling that IPIX Scientific Advisor Degrado would know whether the adverse effect of Heparin was known at the time the trial was designed. Even if you believe the contrary to be true:
"The adverse effect of Heparin was not known at the time the trial was designed."